About Gensynth Laboratories
Gensynth Laboratories is a Healthcare company based in Hyderabad (India). It manufactures USFDA approved pharmaceutical intermediates for global market supply. It operates on a B2B model. The company has 83 employees. Its Indian entity Gensynth Laboratories Private Limited reported revenue of ₹56.86 Cr. Gensynth Laboratories offers products and services including Methyl-1-[(2-cyanobiphenyl-4-yl)methyl]-2-ethoxybenzimidazole-7-carboxylate, Methyl-2-ethoxy-1-[[2’-(1h-tetrazole-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, and 2-Ethoxy-1[(2'(1-triphenylmethyl) 1H-tetrazol-5yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid. Its focus areas include Pharmaceuticals, Intermediates Manufacturing, API Production and Biotech. Its competitors include Viyash, Inventys, Blue Jet Healthcare, Ami organics and Aparna Pharmaceuticals and 4 more; 4 of its 9 listed competitors have raised funding.
Company details
Gensynth Laboratories Pvt. Ltd is a USFDA site approved manufacturer of advanced pharmaceutical intermediates, focusing on expanding product portfolios and providing cost-effective solutions. Located in Pashamylaram near Hyderabad, India, the company operates a fully equipped RD center to support innovation in the pharmaceutical sector. They engage in producing intermediates for APIs like Candesartan Cilexetil, targeting the broader pharmaceutical market without specifying particular clients.
- Headquarters Hyderabad, India
- Employees 83
- SectorsHealthcare
- Email••••••••
- Website gensynthlabs.com
- Legal Name Gensynth Laboratories Private Limited
- Date of Incorporation 23 Dec, 2004
- Jurisdiction Patancheru, Telangana, India
- Annual Revenue₹56.86 Cr
FY 2025 · -29% YoY
- Net Profit₹38.2 Lakh
FY 2025 · 1% margin
- EBITDA₹3.77 Cr
FY 2025 · 7% margin
- Employee Count83
Associated legal entities of Gensynth Laboratories
Gensynth Laboratories operates through Gensynth Laboratories Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gensynth Laboratories Private Limited CIN U24230TG2004PTC044953 | Active | 23 Dec 2004 | Patancheru, Telangana | ₹56.9 Cr | 83 | 5 | View details |
Products & Services of Gensynth Laboratories
Gensynth Laboratories offers a comprehensive portfolio of products and services, including Methyl-1-[(2-cyanobiphenyl-4-yl)methyl]-2-ethoxybenzimidazole-7-carboxylate, Methyl-2-ethoxy-1-[[2’-(1h-tetrazole-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, and 2-Ethoxy-1[(2'(1-triphenylmethyl) 1H-tetrazol-5yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.
Used as intermediate for producing Candesartan Cilexetil API.
Serves as key component in Candesartan Cilexetil synthesis.
Intermediate for Candesartan Cilexetil manufacturing process.
Board of directors of Gensynth Laboratories Private Limited (Gensynth Laboratories)
Gensynth Laboratories Private Limited is the primary company behind Gensynth Laboratories. The board of Gensynth Laboratories Private Limited currently have 5 directors; the longest-serving is Bhimavarapu Sri Rami Reddy, appointed in 2004. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bhimavarapu Sri Rami Reddy DIN 01768703 | Managing Director | 23 Dec 2004 | 21 yrs 9 mo | Gensynth Laboratories Private Limited |
| Prasanthi Emani DIN 06682706 | Director | 23 Dec 2004 | 21 yrs 9 mo | Gensynth Laboratories Private Limited |
| Ravi Gangapalli DIN 03010397 | Managing Director | 10 Oct 2020 | 6 yrs | Gensynth Laboratories Private Limited |
| Madhi Raju Prabhakara Varma DIN 05357457 | Director | 11 May 2024 | 2 yrs 5 mo | Gensynth Laboratories Private Limited |
| Santhi Sudha Gangapalli DIN 05295902 | Director | 18 Jun 2024 | 2 yrs 4 mo | Gensynth Laboratories Private Limited |
Financials of Gensynth Laboratories
Figures of Gensynth Laboratories Private Limited, the primary company behind Gensynth Laboratories, for FY 2025. Revenue was ₹56.86 Cr (-29% year on year). Net profit was ₹38.2 Lakh (1% margin). EBITDA was ₹3.77 Cr (7% margin). Revenue has grown at a compounded annual rate of +20% over three years and +12% over five years.
- ₹56.86 CrRevenue · FY 2025 · -29% YoY
- ₹38.2 LakhNet profit · 1% margin
- ₹3.77 CrEBITDA · 7% margin
- ₹3.52 CrPaid-up capital
- 83Employees (provident fund records)
- +20%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Gensynth Laboratories Private Limited are on its company page.
Detailed financial statements for Gensynth Laboratories
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Gensynth Laboratories
Gensynth Laboratories has 9 listed competitors in our database, 4 of them funded. They include Viyash, Inventys, Blue Jet Healthcare, Ami organics and Aparna Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viyash.com | 2019 | Hyderabad, India | $120.02M | 277 | APIs and intermediates are manufactured by Viyash as a CDMO. | |
| inventys.in | 2005 | Mumbai, India | $64.34M | 219 | Actives, advanced intermediates, and specialty chemicals are custom manufactured. | |
| bluejethealthcare.com | 1969 | Mumbai, India | – | 476 | CDMO focused on manufacturing, supplier, and development of intermediates & APIs | |
| amiorganics.com | 2007 | Surat, India | – | 4 | Advanced API intermediates are manufactured for pharmaceutical use. | |
| aparnapharma.com | 2008 | Hyderabad, India | $674,328 | 328 | API intermediates are manufactured by Aparna Pharmaceuticals as a CDMO. | |
| dudechem.com | 2019 | Berlin, Germany | $6.98M | – | CDMO focused on manufacturing of APIs and intermediates | |
| hindyslab.com | 2007 | Hyderabad, India | – | 285 | Manufactures and exports pharmaceutical intermediates for global markets. | |
| hsbiopharm.com | 2004 | Hangzhou, China | – | – | APIs, intermediates, and finished dosage forms are manufactured. | |
| enantilabs.com | 2007 | Hyderabad, India | – | 178 | Enanti Labs produces pharmaceutical intermediates and APIs in India with quality focus. |
Detailed competitors of Gensynth Laboratories
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Gensynth Laboratories (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Gensynth Laboratories
Gensynth Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Gensynth Laboratories has 83 employees.
The primary company behind Gensynth Laboratories, Gensynth Laboratories Private Limited, reported revenue of ₹56.86 Cr for FY 2025, down 29% year on year.
Gensynth Laboratories Pvt. Ltd is a USFDA site approved manufacturer of advanced pharmaceutical intermediates, focusing on expanding product portfolios and providing cost-effective solutions. Located in Pashamylaram near Hyderabad, India, the company operates a fully equipped RD center to support innovation in the pharmaceutical sector. They engage in producing intermediates for APIs like Candesartan Cilexetil, targeting the broader pharmaceutical market without specifying particular clients.
Gensynth Laboratories's top competitors include Inventys, Viyash and Blue Jet Healthcare.
Gensynth Laboratories offers Methyl-1-[(2-cyanobiphenyl-4-yl)methyl]-2-ethoxybenzimidazole-7-carboxylate, Methyl-2-ethoxy-1-[[2’-(1h-tetrazole-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, and 2-Ethoxy-1[(2'(1-triphenylmethyl) 1H-tetrazol-5yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.
Gensynth Laboratories operates through Gensynth Laboratories Private Limited.
The legal entities of Gensynth Laboratories currently have 5 directors, including Santhi Sudha Gangapalli, Bhimavarapu Sri Rami Reddy, Ravi Gangapalli and others.